The efficacy of tucatinib plus trastuzumab and capecitabine was evaluated in an international randomized (HER2CLIMB) study that included locally advanced unresectable or metastatic HER2-positive breast cancer, with or without brain metastases [49]. This evidence concerns the gene ERBB2 and breast cancer.